Microdosing of a Carbon-14 Labeled Protein in Healthy Volunteers Accurately Predicts Its Pharmacokinetics at Therapeutic Dosages.
Vlaming, M LH 1; van Duijn, E 1; Dillingh, M R 2; Brands, R 3; Windhorst, A D 4; Hendrikse, N H 5; Bosgra, S 1; Burggraaf, J 2; de Koning, M C 1; Fidder, A 1; Mocking, J AJ 1; Sandman, H 1; de Ligt, R AF 1; Fabriek, B O 1; Pasman, W J 1; Seinen, W 3,6; Alves, T 7; Carrondo, M 7; Peixoto, C 7; Peeters, P AM 2; Vaes, W HJ 1
[Miscellaneous Article] Clinical Pharmacology & Therapeutics. 98(2):196-204, August 2015.

(Format: HTML, PDF)

: Preclinical development of new biological entities (NBEs), such as human protein therapeutics, requires considerable expenditure of time and costs. Poor prediction of pharmacokinetics in humans further reduces net efficiency. In this study, we show for the first time that pharmacokinetic data of NBEs in humans can be successfully obtained early in the drug development process by the use of microdosing in a small group of healthy subjects combined with ultrasensitive accelerator mass spectrometry (AMS). After only minimal preclinical testing, we performed a first-in-human phase 0/phase 1 trial with a human recombinant therapeutic protein (RESCuing Alkaline Phosphatase, human recombinant placental alkaline phosphatase [hRESCAP]) to assess its safety and kinetics. Pharmacokinetic analysis showed dose linearity from microdose (53 [mu]g) [14C]-hRESCAP to therapeutic doses (up to 5.3 mg) of the protein in healthy volunteers. This study demonstrates the value of a microdosing approach in a very small cohort for accelerating the clinical development of NBEs.

(C) Mosby-Year Book Inc. 2015. All Rights Reserved.